File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker
  • Basic View
  • Metadata View
  • XML View
TitleEnhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker
 
AuthorsChen, L1 5
Ho, DWY1
Lee, NPY1
Sun, S1
Lam, B1 3
Wong, KF1 4
Yi, X1 5
Lau, GK1
Ng, EWY6
Poon, TCW6
Lai, PBS6
Cai, Z2
Peng, J5
Leng, X5
Poon, RTP1
Luk, JM1 4
 
Issue Date2010
 
PublisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
 
CitationAnnals Of Surgical Oncology, 2010, v. 17 n. 9, p. 2518-2525 [How to Cite?]
DOI: http://dx.doi.org/10.1245/s10434-010-1038-8
 
AbstractBackground: Biomarkers for accurate diagnosis of early hepatocellular carcinoma (HCC) are limited in number and clinical validation. We applied SELDI-TOF-MS ProteinChip technology to identify serum profile for distinguishing HCC and liver cirrhosis (LC) and to compare the accuracy of SELDI-TOF-MS profile and alpha-fetoprotein (AFP) level in HCC diagnosis. Patients and Methods: Serum samples were obtained from 120 HCC and 120 LC patients for biomarker discovery and validation studies. ProteinChip technology was employed for generating SELDI-TOF proteomic features and analyzing serum proteins/peptides. Results: A diagnostic model was established by CART algorithm, which is based on 5 proteomic peaks with m/z values at 3324, 3994, 4665, 4795, and 5152. In the training set, the CART algorithm could differentiate HCC from LC subjects with a sensitivity and specificity of 98% and 95%, respectively. The results were assessed in blind validation using separate cohorts of 60 HCC and 60 LC patients, with an accuracy of 83% for HCC and 92% for LC patients. The diagnostic odd ratio (DOR) indicated that SELDI-TOF proteomic signature could achieve better diagnostic performance than serum AFP level at a cutoff of 20 ng/mL (AFP 20) (92.72 vs 9.11), particularly superior for early-stage HCC (87% vs 54%). Importantly, a combined use of both tests could enhance the detection of HCC (sensitivity, 95%; specificity, 98%; DOR, 931). Conclusion: Serum SELDI-TOF proteomic signature, alone or in combination with AFP marker, promises to be a good tool for early diagnosis and/screening of HCC in at-risk population with liver cirrhosis. © 2010 Society of Surgical Oncology.
 
ISSN1068-9265
2013 Impact Factor: 3.943
 
DOIhttp://dx.doi.org/10.1245/s10434-010-1038-8
 
PubMed Central IDPMC2924503
 
ISI Accession Number IDWOS:000281858600035
Funding AgencyGrant Number
National Natural Science Foundation of China30331160411
Hong Kong Research Grants CouncilN_HKU718/03
Natural Science Foundation of Beijing7042032
Funding Information:

This study was jointly supported by the Scheme of National Natural Science Foundation of China (30331160411), the Hong Kong Research Grants Council (N_HKU718/03), and the Natural Science Foundation of Beijing (7042032). We acknowledge Dr. CK Hui for his clinical expertise and Professor QY He for his expert opinions and advices on protein identification in serum samples.

 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorChen, L
 
dc.contributor.authorHo, DWY
 
dc.contributor.authorLee, NPY
 
dc.contributor.authorSun, S
 
dc.contributor.authorLam, B
 
dc.contributor.authorWong, KF
 
dc.contributor.authorYi, X
 
dc.contributor.authorLau, GK
 
dc.contributor.authorNg, EWY
 
dc.contributor.authorPoon, TCW
 
dc.contributor.authorLai, PBS
 
dc.contributor.authorCai, Z
 
dc.contributor.authorPeng, J
 
dc.contributor.authorLeng, X
 
dc.contributor.authorPoon, RTP
 
dc.contributor.authorLuk, JM
 
dc.date.accessioned2010-10-19T04:35:45Z
 
dc.date.available2010-10-19T04:35:45Z
 
dc.date.issued2010
 
dc.description.abstractBackground: Biomarkers for accurate diagnosis of early hepatocellular carcinoma (HCC) are limited in number and clinical validation. We applied SELDI-TOF-MS ProteinChip technology to identify serum profile for distinguishing HCC and liver cirrhosis (LC) and to compare the accuracy of SELDI-TOF-MS profile and alpha-fetoprotein (AFP) level in HCC diagnosis. Patients and Methods: Serum samples were obtained from 120 HCC and 120 LC patients for biomarker discovery and validation studies. ProteinChip technology was employed for generating SELDI-TOF proteomic features and analyzing serum proteins/peptides. Results: A diagnostic model was established by CART algorithm, which is based on 5 proteomic peaks with m/z values at 3324, 3994, 4665, 4795, and 5152. In the training set, the CART algorithm could differentiate HCC from LC subjects with a sensitivity and specificity of 98% and 95%, respectively. The results were assessed in blind validation using separate cohorts of 60 HCC and 60 LC patients, with an accuracy of 83% for HCC and 92% for LC patients. The diagnostic odd ratio (DOR) indicated that SELDI-TOF proteomic signature could achieve better diagnostic performance than serum AFP level at a cutoff of 20 ng/mL (AFP 20) (92.72 vs 9.11), particularly superior for early-stage HCC (87% vs 54%). Importantly, a combined use of both tests could enhance the detection of HCC (sensitivity, 95%; specificity, 98%; DOR, 931). Conclusion: Serum SELDI-TOF proteomic signature, alone or in combination with AFP marker, promises to be a good tool for early diagnosis and/screening of HCC in at-risk population with liver cirrhosis. © 2010 Society of Surgical Oncology.
 
dc.description.naturepublished_or_final_version
 
dc.description.otherSpringer Open Choice, 01 Dec 2010
 
dc.identifier.citationAnnals Of Surgical Oncology, 2010, v. 17 n. 9, p. 2518-2525 [How to Cite?]
DOI: http://dx.doi.org/10.1245/s10434-010-1038-8
 
dc.identifier.doihttp://dx.doi.org/10.1245/s10434-010-1038-8
 
dc.identifier.eissn1534-4681
 
dc.identifier.epage2525
 
dc.identifier.hkuros182516
 
dc.identifier.isiWOS:000281858600035
Funding AgencyGrant Number
National Natural Science Foundation of China30331160411
Hong Kong Research Grants CouncilN_HKU718/03
Natural Science Foundation of Beijing7042032
Funding Information:

This study was jointly supported by the Scheme of National Natural Science Foundation of China (30331160411), the Hong Kong Research Grants Council (N_HKU718/03), and the Natural Science Foundation of Beijing (7042032). We acknowledge Dr. CK Hui for his clinical expertise and Professor QY He for his expert opinions and advices on protein identification in serum samples.

 
dc.identifier.issn1068-9265
2013 Impact Factor: 3.943
 
dc.identifier.issue9
 
dc.identifier.openurl
 
dc.identifier.pmcidPMC2924503
 
dc.identifier.pmid20354800
 
dc.identifier.scopuseid_2-s2.0-77956345377
 
dc.identifier.spage2518
 
dc.identifier.urihttp://hdl.handle.net/10722/124045
 
dc.identifier.volume17
 
dc.languageeng
 
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.annalssurgicaloncology.org
 
dc.publisher.placeUnited States
 
dc.relation.ispartofAnnals of Surgical Oncology
 
dc.relation.referencesReferences in Scopus
 
dc.rightsThe original publication is available at www.springerlink.com
 
dc.rightsThe Author(s)
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshLiver Neoplasms - blood - diagnosis
 
dc.subject.meshProteome - analysis
 
dc.subject.meshSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods
 
dc.subject.meshTumor Markers, Biological - blood
 
dc.subject.meshalpha-Fetoproteins - metabolism
 
dc.titleEnhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chen, L</contributor.author>
<contributor.author>Ho, DWY</contributor.author>
<contributor.author>Lee, NPY</contributor.author>
<contributor.author>Sun, S</contributor.author>
<contributor.author>Lam, B</contributor.author>
<contributor.author>Wong, KF</contributor.author>
<contributor.author>Yi, X</contributor.author>
<contributor.author>Lau, GK</contributor.author>
<contributor.author>Ng, EWY</contributor.author>
<contributor.author>Poon, TCW</contributor.author>
<contributor.author>Lai, PBS</contributor.author>
<contributor.author>Cai, Z</contributor.author>
<contributor.author>Peng, J</contributor.author>
<contributor.author>Leng, X</contributor.author>
<contributor.author>Poon, RTP</contributor.author>
<contributor.author>Luk, JM</contributor.author>
<date.accessioned>2010-10-19T04:35:45Z</date.accessioned>
<date.available>2010-10-19T04:35:45Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Annals Of Surgical Oncology, 2010, v. 17 n. 9, p. 2518-2525</identifier.citation>
<identifier.issn>1068-9265</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/124045</identifier.uri>
<description.abstract>Background: Biomarkers for accurate diagnosis of early hepatocellular carcinoma (HCC) are limited in number and clinical validation. We applied SELDI-TOF-MS ProteinChip technology to identify serum profile for distinguishing HCC and liver cirrhosis (LC) and to compare the accuracy of SELDI-TOF-MS profile and alpha-fetoprotein (AFP) level in HCC diagnosis. Patients and Methods: Serum samples were obtained from 120 HCC and 120 LC patients for biomarker discovery and validation studies. ProteinChip technology was employed for generating SELDI-TOF proteomic features and analyzing serum proteins/peptides. Results: A diagnostic model was established by CART algorithm, which is based on 5 proteomic peaks with m/z values at 3324, 3994, 4665, 4795, and 5152. In the training set, the CART algorithm could differentiate HCC from LC subjects with a sensitivity and specificity of 98% and 95%, respectively. The results were assessed in blind validation using separate cohorts of 60 HCC and 60 LC patients, with an accuracy of 83% for HCC and 92% for LC patients. The diagnostic odd ratio (DOR) indicated that SELDI-TOF proteomic signature could achieve better diagnostic performance than serum AFP level at a cutoff of 20 ng/mL (AFP 20) (92.72 vs 9.11), particularly superior for early-stage HCC (87% vs 54%). Importantly, a combined use of both tests could enhance the detection of HCC (sensitivity, 95%; specificity, 98%; DOR, 931). Conclusion: Serum SELDI-TOF proteomic signature, alone or in combination with AFP marker, promises to be a good tool for early diagnosis and/screening of HCC in at-risk population with liver cirrhosis. &#169; 2010 Society of Surgical Oncology.</description.abstract>
<language>eng</language>
<publisher>Springer New York LLC. The Journal&apos;s web site is located at http://www.annalssurgicaloncology.org</publisher>
<relation.ispartof>Annals of Surgical Oncology</relation.ispartof>
<rights>The original publication is available at www.springerlink.com</rights>
<rights>The Author(s)</rights>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject.mesh>Liver Neoplasms - blood - diagnosis</subject.mesh>
<subject.mesh>Proteome - analysis</subject.mesh>
<subject.mesh>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods</subject.mesh>
<subject.mesh>Tumor Markers, Biological - blood</subject.mesh>
<subject.mesh>alpha-Fetoproteins - metabolism</subject.mesh>
<title>Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1068-9265&amp;volume=17&amp;issue=9&amp;spage=2518&amp;epage=2525&amp;date=2010&amp;atitle=Enhanced+detection+of+early+hepatocellular+carcinoma+by+serum+SELDI-TOF+proteomic+signature+combined+with+alpha-fetoprotein+marker</identifier.openurl>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.1245/s10434-010-1038-8</identifier.doi>
<identifier.pmid>20354800</identifier.pmid>
<identifier.pmcid>PMC2924503</identifier.pmcid>
<identifier.scopus>eid_2-s2.0-77956345377</identifier.scopus>
<identifier.hkuros>182516</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-77956345377&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>17</identifier.volume>
<identifier.issue>9</identifier.issue>
<identifier.spage>2518</identifier.spage>
<identifier.epage>2525</identifier.epage>
<identifier.eissn>1534-4681</identifier.eissn>
<identifier.isi>WOS:000281858600035</identifier.isi>
<publisher.place>United States</publisher.place>
<description.other>Springer Open Choice, 01 Dec 2010</description.other>
<bitstream.url>http://hub.hku.hk/bitstream/10722/124045/1/10434_2010_Article_1038.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. Hong Kong Baptist University
  3. University of Cambridge
  4. National University of Singapore
  5. Peking University
  6. Chinese University of Hong Kong